Report finds no evidence that ‘microdosing’ weight loss drugs is safe or effective

• A trend of “microdosing” GLP-1 drugs, such as Ozempic and Mounjaro, for longevity is spreading online, despite these medications being approved for type 2 diabetes and weight management.
• Experts and pharmaceutical companies confirm there is virtually no published scientific evidence to support the safety or effectiveness of microdosing GLP-1s for extending lifespan.
• Cardiologist Eric Topol described the practice as an unsubstantiated “craze,” emphasizing it is premature to conclude if small doses can lead to a longer life.
• While standard doses of GLP-1s are known to reduce inflammation and may protect the brain, it is unclear if microdoses offer similar benefits or what constitutes an effective microdose.
• The FDA has issued warnings against using unapproved versions of GLP-1 drugs, and pharmaceutical companies like Eli Lilly and Novo Nordisk have voiced concerns regarding misinformation and unapproved products.

IN FULL

The internet is convinced ‘microdosing’ weight-loss drugs will help you live long. Scientists say there’s no evidence it does